Pfizer Inc

PFE-N

NYSE:PFE

38.14
2.02 (5.03%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
January 17, 2020
He takes a contrarian view as the company reorganizes its business. They are making acquisitions including in the oncology and vaccine business. There are some big drugs coming out of the pipeline. They are becoming more focused on R&D and building out their pipeline. They have around 15 phase 3 drugs right now. Patent expiry is what you have to watch for with this name. (Analysts’ price target is $42.54)
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 17, 2020
He takes a contrarian view as the company reorganizes its business. They are making acquisitions including in the oncology and vaccine business. There are some big drugs coming out of the pipeline. They are becoming more focused on R&D and building out their pipeline. They have around 15 phase 3 drugs right now. Patent expiry is what you have to watch for with this name. (Analysts’ price target is $42.54)
COMMENT
COMMENT
January 17, 2020

He was concerned that GSK was getting more growth focused. They spun off their consumer products with Novartis, giving up their oncology department. Now they have a joint venture with Pfizer. Having it as a longterm asset is probably positive.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 17, 2020

He was concerned that GSK was getting more growth focused. They spun off their consumer products with Novartis, giving up their oncology department. Now they have a joint venture with Pfizer. Having it as a longterm asset is probably positive.

PAST TOP PICK
PAST TOP PICK
January 10, 2020
(A Top Pick Feb 08/19, Down 4%) All the drug stocks look so cheap here. His model price is $50.43.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 10, 2020
(A Top Pick Feb 08/19, Down 4%) All the drug stocks look so cheap here. His model price is $50.43.
PAST TOP PICK
PAST TOP PICK
December 5, 2019
(A Top Pick Feb 08/19, Down 7%) All the drugs have been moving spectacularly. There is a lot of value. His model price is 48.79 or a 28% upside. If we have a fall, these stocks will do very well.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
December 5, 2019
(A Top Pick Feb 08/19, Down 7%) All the drugs have been moving spectacularly. There is a lot of value. His model price is 48.79 or a 28% upside. If we have a fall, these stocks will do very well.
PAST TOP PICK
PAST TOP PICK
November 21, 2019
(A Top Pick Dec 06/18, Down 13%) Under pressure due to patent loss and divesting off-patent division. Dividend is 3.9% and looks secure. Political noise has hurt healthcare. This is an opportunity. Starting to launch potential blockbuster drugs.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 21, 2019
(A Top Pick Dec 06/18, Down 13%) Under pressure due to patent loss and divesting off-patent division. Dividend is 3.9% and looks secure. Political noise has hurt healthcare. This is an opportunity. Starting to launch potential blockbuster drugs.
PAST TOP PICK
PAST TOP PICK
November 19, 2019
(A Top Pick Sep 09/19, Up 4%) He doesn't see upside in the drug space. He won't sell it, but won't add to it. This sector will be quiet as others rally. Hold.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
November 19, 2019
(A Top Pick Sep 09/19, Up 4%) He doesn't see upside in the drug space. He won't sell it, but won't add to it. This sector will be quiet as others rally. Hold.
HOLD
HOLD
October 24, 2019
Dropped off with the spinoff. Very good dividend. Undervalued here because of political pressure. That's an opportunity. Healthcare companies tend to do well when the economic cycle matures. Be patient. Value stocks are emerging from their underperformance. Yield is 4%. (Analysts’ price target is $41.77)
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 24, 2019
Dropped off with the spinoff. Very good dividend. Undervalued here because of political pressure. That's an opportunity. Healthcare companies tend to do well when the economic cycle matures. Be patient. Value stocks are emerging from their underperformance. Yield is 4%. (Analysts’ price target is $41.77)
WAIT
WAIT
October 22, 2019
He liked this before, but has suffered a setback. The MFV is 37% higher than the present price. The earnings forecasts are rolling over, which worries him--it's a warning of bad things to come. He wouldn't buy this unless it fell to $30. Pays a 4% yield. Wait.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 22, 2019
He liked this before, but has suffered a setback. The MFV is 37% higher than the present price. The earnings forecasts are rolling over, which worries him--it's a warning of bad things to come. He wouldn't buy this unless it fell to $30. Pays a 4% yield. Wait.
DON'T BUY
DON'T BUY
October 17, 2019

Real topline struggles over the past decade. Blockbusters go off patent and have to be replaced. Like bailing a leaky boat. You can only cut costs to make money for so long. If he had to pick one, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
October 17, 2019

Real topline struggles over the past decade. Blockbusters go off patent and have to be replaced. Like bailing a leaky boat. You can only cut costs to make money for so long. If he had to pick one, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.

DON'T BUY
DON'T BUY
September 24, 2019
Weak in the healthcare space. It's currently at support level, and it is entering seasonal weakness in mid-October.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 24, 2019
Weak in the healthcare space. It's currently at support level, and it is entering seasonal weakness in mid-October.
TOP PICK
TOP PICK
September 16, 2019
He's bought and sold this at $43. They're Upjohn division is merging with Mylan and will spin it out. This will likely lead to the stock returning to the mid-$40's (Analysts’ price target is $42.75)
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 16, 2019
He's bought and sold this at $43. They're Upjohn division is merging with Mylan and will spin it out. This will likely lead to the stock returning to the mid-$40's (Analysts’ price target is $42.75)
TOP PICK
TOP PICK
September 6, 2019
It has long term support levels. At a great spot, and it is consolidating well. Would take advantage of the pullback here. The risk is to go up not down.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 6, 2019
It has long term support levels. At a great spot, and it is consolidating well. Would take advantage of the pullback here. The risk is to go up not down.
DON'T BUY
DON'T BUY
August 22, 2019

He would not buy it at this point. They recently agreed to by Mylan and with Teva have been challenged on pricing of their generic drugs. It has grown through cost cutting. Revenue growth is muted at best.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
August 22, 2019

He would not buy it at this point. They recently agreed to by Mylan and with Teva have been challenged on pricing of their generic drugs. It has grown through cost cutting. Revenue growth is muted at best.

DON'T BUY
DON'T BUY
August 20, 2019
The US healthcare system is under attack by politicians until the election. Trump wants to put them out of business, so why mess with this space? Patent expirations are another hurdle.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
August 20, 2019
The US healthcare system is under attack by politicians until the election. Trump wants to put them out of business, so why mess with this space? Patent expirations are another hurdle.
DON'T BUY
DON'T BUY
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Showing 1 to 15 of 670 entries